ADRIATIC Study Highlights Survival Gains With Durvalumab in LS-SCLC
Aakash Desai, MD, MPH, discusses the ADRIATIC study in limited-stage small cell lung cancer.
Aakash Desai, MD, MPH, thoracic and phase 1 medical oncologist and assistant professor at the O’Neal Cancer Center at the University of Alabama, Birmingham, discusses the ADRIATIC study (NCT03703297) in limited-stage small cell lung cancer (LS-SCLC).
The ADRIATIC study evaluated the use of durvalumab (Imfinzi) as consolidation treatment after concurrent chemoradiation in patients with LS-SCLC. Improved survival outcomes were observed with this consolidation treatment, according to data shared during a press briefing at the 2024 American Society of Clinical Oncology Annual Meeting.
At a median follow-up of 37.2 months (range, 0.1-60.9), the median overall survival was 55.9 months (95% CI, 37.3-not evaluable) for patients treated with durvalumab (n = 264) vs 33.4 months (95% CI, 25.5-39.9) for those treated with placebo (n = 266). This translated to a 27% reduction in the risk of death (HR, 0.73; 95% CI, 0.57-0.93; P = .0104).
Transcription:
0:09 | I think this has changed and will change clinical practice once it is approved. The ADRIATIC study studied durvalumab as consolidation treatment for patients with limited-stage small cell lung cancer. Patients with limited-stage small cell lung cancer currently get chemoradiation without any consolidative treatment. This has been sort of the standard of care for a couple of decades. With this particular study, they did look at overall survival as a dual primary end point, but also PFS. We did see that the median PFS was improved with durvalumab at 16.6 vs 9.2 months.
0:53 | In terms of the [overall survival], we also saw median overall survival benefit with durvalumab at 55 months vs 33 with placebo. I think this is an important advance, especially for small cell lung cancer, which is a very difficult to treat disease and an aggressive disease. For those patients with limited-stage [SCLC], the option of incorporating immunotherapy and the outcomes and efficacy that we see is exciting, and I definitely will use it in the clinic once it is approved.
